Thermo Fisher Scientific (NYSE:TMO) Price Target Cut to $620.00 by Analysts at Robert W. Baird

Thermo Fisher Scientific (NYSE:TMO) had its target price decreased by Robert W. Baird from $621.00 to $620.00 in a research note issued to investors on Thursday, Benzinga reports. Robert W. Baird currently has an outperform rating on the medical research company’s stock.

Other research analysts have also recently issued reports about the stock. Royal Bank of Canada lifted their price target on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an outperform rating in a research report on Thursday, February 1st. Raymond James lifted their price objective on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an outperform rating in a research note on Thursday, February 1st. Sanford C. Bernstein reiterated a market perform rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Barclays lowered shares of Thermo Fisher Scientific from an overweight rating to an equal weight rating and lifted their price objective for the company from $475.00 to $555.00 in a research note on Wednesday, January 24th. Finally, The Goldman Sachs Group lifted their price objective on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a buy rating in a research note on Wednesday, April 10th. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of Moderate Buy and an average price target of $606.76.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $573.60 on Thursday. Thermo Fisher Scientific has a 12-month low of $415.60 and a 12-month high of $603.82. The stock has a market capitalization of $218.95 billion, a P/E ratio of 36.79, a P/E/G ratio of 2.42 and a beta of 0.80. The firm’s 50-day moving average is $573.60 and its two-hundred day moving average is $530.40. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.39.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. The firm had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. Equities analysts predict that Thermo Fisher Scientific will post 21.56 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date of this dividend was Thursday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s payout ratio is currently 10.01%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now owns 12,901 shares of the company’s stock, valued at $7,250,362. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $74,039,491.68. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The disclosure for this sale can be found here. Insiders sold a total of 50,277 shares of company stock valued at $28,513,384 over the last 90 days. 0.32% of the stock is owned by company insiders.

Institutional Investors Weigh In On Thermo Fisher Scientific

Institutional investors have recently bought and sold shares of the stock. WCM Investment Management LLC lifted its holdings in Thermo Fisher Scientific by 0.3% in the fourth quarter. WCM Investment Management LLC now owns 989,837 shares of the medical research company’s stock worth $527,524,000 after purchasing an additional 2,928 shares during the period. Phoenix Holdings Ltd. lifted its holdings in Thermo Fisher Scientific by 21.4% in the third quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company’s stock worth $4,750,000 after purchasing an additional 1,654 shares during the period. DMC Group LLC lifted its holdings in Thermo Fisher Scientific by 16.5% in the third quarter. DMC Group LLC now owns 592 shares of the medical research company’s stock worth $300,000 after purchasing an additional 84 shares during the period. S. R. Schill & Associates raised its position in Thermo Fisher Scientific by 106.3% in the fourth quarter. S. R. Schill & Associates now owns 1,537 shares of the medical research company’s stock worth $816,000 after acquiring an additional 792 shares in the last quarter. Finally, Check Capital Management Inc. CA bought a new stake in Thermo Fisher Scientific in the third quarter worth about $219,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.